Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

AEGR 22.81 -0.14 (-0.61%)
price chart
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ, after the company ...
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca  GlobeNewswire (press release)
Front Runners: Tesla Motors (TSLA), Aegerion Pharmaceuticals (AEGR), AAC ...  Wall Street Pit
Related articles »  
Aegerion Pharmaceuticals (AEGR) Stock Downgraded Today at Jefferies
"We rate AEGERION PHARMACEUTICALS INC (AEGR) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared ...
Aegerion Pharmaceuticals (AEGR) Earnings Crushes Shares  Wall Street Pit
Aegerion Falls On Disappointing Earnings  Bidness ETC
Related articles »  
Why Aegerion Pharmaceuticals Inc. Shares Briefly Tumbled
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company developing therapies to treat rare and fatal diseases, tumbled briefly by as much as 18% after reporting its fourth quarter earnings results before the opening bell.
Aegerion Pharmaceuticals, Inc. (AEGR) news: Aegerion Pharmaceuticals ...  Seeking Alpha
Related articles »  
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Aegerion Pharmaceuticals ...
Meet The Biopharma Stock That Lost 34% Last Week  Benzinga
Aegerion Downgraded As Stock Sheds 41% On Disappointing Q3 Results  Bidness ETC
Related articles »  
Is Aegerion Pharmaceuticals, Inc. (AEGR) Ready to Breakout?
Aegerion Pharmaceuticals, Inc. (AEGR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Related articles »  
Aegerion Pharmaceuticals, Inc. (AEGR): Broadfin Boosts Stake Getting on Board ...
Kevin Kotler's New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).
Related articles »  
Can Aegerion Still Rise 70%?
Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) should have a slogan that says �We love volatility.� The biotech stock now trades for just under $60 after its earnings report, but the 52-week trading range is $29.61 to $101.00.
Related articles »  
Why Aegerion Pharmaceuticals, Inc. Shares Sank Like a Stone
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on therapies to treat rare and unmet diseases, dipped as much as 14% after reporting its preliminary 2013 and 2014 sales guidance and disclosing a ...
Aegerion Pharmaceuticals Reports Preliminary 2013 Net Product Sales, Its ...  GlobeNewswire (press release)
Aegerion Pharmaceuticals, Inc. (AEGR): Aegerion discloses DoJ subpoena ...  Seeking Alpha
Related articles »  
Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds' bullishness. Not only did Steve Cohen's Point72 Asset Management disclose an increase in its exposure to the company today, but also Matt Sirovich and Jeremy Mindich's ...
Related articles »  
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
CAMBRIDGE, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases ...
Stocks Buzz: Aegerion Pharmaceuticals (NASDAQ:AEGR), Vodafone Group Plc ...  Property Mentor
Related articles »